Does Risperdal Reduce Irritability in Children with Autism?
Risperdal (risperidone) is FDA-approved for treating irritability associated with autistic disorder in children and adolescents aged 5-16 years, based on two pivotal 8-week, placebo-controlled trials involving 101 and 98 patients, respectively. In these studies, risperidone doses of 0.5-1.17 mg/day reduced irritability scores on the Aberrant Behavior Checklist-Irritability subscale by 57-64% from baseline, compared to 14-15% with placebo (p<0.0001). Improvements were seen in tantrums, aggression, and self-injury.[1][2]
How Large Are the Clinical Improvements?
Effect sizes were moderate to large (Cohen's d ≈ 0.9-1.2) across trials, with 69-73% of risperidone patients rated as "much improved" or "very much improved" on the Clinical Global Impression-Change scale, versus 12-14% on placebo. Maintenance therapy over 6 months showed sustained benefits, with relapse rates of 18% on risperidone versus 46% after withdrawal.[3]
What Do Long-Term Studies Show?
Open-label extensions up to 3 years confirm ongoing irritability reduction, though with diminishing returns and higher dropout due to side effects. A 2009 meta-analysis of 5 RCTs (n=458) found risperidone superior to placebo for core symptoms like irritability (SMD -0.87; 95% CI -1.20 to -0.54), but effects wane after 6-12 months without dose adjustments.[4]
What Side Effects Limit Its Use?
Weight gain (mean 4-7 kg in first year), elevated prolactin (up to 3x baseline), somnolence, and extrapyramidal symptoms occurred in 20-40% of patients, more than placebo. Hyperprolactinemia risks gynecomastia or menstrual irregularities. Long-term metabolic risks include diabetes and dyslipidemia, prompting black-box warnings for elderly dementia use (not autism-approved).[1][5]
How Does It Compare to Other Treatments?
Risperdal outperforms placebo more than aripiprazole (another approved atypical antipsychotic; effect size 0.8 vs. 1.1) but similar to haloperidol, with better tolerability. Non-drug options like risperdal plus behavioral therapy show additive effects, but stimulants or SSRIs are less effective for irritability. Guidelines (AACAP) recommend antipsychotics only after behavioral interventions fail.[6]
Who Responds Best and When to Start?
Boys under 12 with moderate-severe irritability respond most robustly. Start at 0.25 mg/day, titrate to 0.5-2.5 mg/day based on weight. Not approved for adults or core autism symptoms like social deficits.[2]
[1] FDA Label for Risperdal
[2] NEJM 2002: Risperidone in Children with Autism
[3] NEJM 2005: Maintenance Risperidone Treatment
[4] Pediatrics 2009: Meta-Analysis of Antipsychotics in Autism
[5] JAACAP 2009: Safety Review
[6] AACAP Practice Parameters for Autism